Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer

Sci Rep. 2023 Apr 8;13(1):5789. doi: 10.1038/s41598-023-31587-8.

Abstract

The main aim of this study was to evaluate the prognostic value of radiomic approach in pre-therapeutic 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET/CT) in a large cohort of patients with gastro-esophageal junction cancer (GEJC). This was a retrospective monocenter study including 97 consecutive patients with GEJC who underwent a pre-therapeutic FDG-PET and were followed up for 3 years. Standard first-order radiomic PET indices including SUVmax, SUVmean, SUVpeak, MTV and TLG and 32 textural features (TFs) were calculated using LIFEx software on PET imaging. Prognostic significance of these parameters was assessed in univariate and multivariate analysis. Relapse-free survival (RFS) and overall survival (OS) were respectively chosen as primary and secondary endpoints. An internal validation cohort was used by randomly drawing one-third of included patients. The main characteristics of this cohort were: median age of 65 years [41-88], sex ratio H/F = 83/14, 81.5% of patients with a histopathology of adenocarcinoma and 43.3% with a stage IV disease. The median follow-up was 28.5 months [4.2-108.5]. Seventy-seven (79.4%) patients had locoregional or distant progression or recurrence and 71 (73.2%) died. In univariate analysis, SUVmean, Histogram-Entropy and 2 TFs (GLCM-Homogeneity and GLCM-Energy) were significantly correlated with RFS and OS, as well as 2 others TFs (GLRLM-LRE and GLRLM-GLNU) with OS only. In multivariate analysis, Histogram-Entropy remained an independent prognostic factor of both RFS and OS whereas SUVmean was an independent prognostic factor of OS only. These results were partially confirmed in our internal validation cohort of 33 patients. Our results suggest that radiomic approach reveals independent prognostic factors for survival in patients with GEJC.

MeSH terms

  • Adenocarcinoma* / diagnostic imaging
  • Adenocarcinoma* / mortality
  • Adenocarcinoma* / therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Esophageal Neoplasms* / diagnostic imaging
  • Esophageal Neoplasms* / mortality
  • Esophageal Neoplasms* / therapy
  • Esophagogastric Junction* / diagnostic imaging
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography / methods
  • Preoperative Period
  • Prognosis
  • Radiopharmaceuticals
  • Retrospective Studies
  • Stomach Neoplasms* / diagnostic imaging
  • Stomach Neoplasms* / mortality
  • Stomach Neoplasms* / therapy
  • Tumor Burden

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals